
CureDuchenne Ventures Early Funding Shows Promising Returns as FDA Fast Tracks Edgewise’s EDG-5506
CureDuchenne Ventures’ early funding of Edgewise in September of 2019 is returning more good news. In November of 2020, Edgewise began its Phase 1 clinical trial on EDG-5506, an experimental […]








